No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 6 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Apollomics, Inc. (APLM) stock was $23.00 as of Oct 5, 2026, 3:59 PM EDT, down 1.16% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +26.1% · 3-year avg -57.6%/yr
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements.
Biotechnology · Foster City, CA
Next Earnings Date
Apr 1, 2027
177 days away
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
$0.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1APLM | $50.51M | $23.00 | -1.16% | +26.12% | N/A | N/A | N/A |
| 2COCH | $50.25M | $0.65 | -3.98% | -19.94% | -41.73% | N/A | vs APLM |
| 3CLNN | $49.96M | $3.91 | -4.17% | -62.62% | -51.16% | N/A | vs APLM |
| 4DWTX | $51.12M | $1.52 | +4.11% | -76.12% | -58.44% | N/A | vs APLM |
| 5EXOZ | $51.23M | $5.52 | -4.33% | -58.32% | N/A | N/A | vs APLM |
| 6CELU | $49.50M | $1.71 | +6.87% | -19.63% | -52.57% | N/A | vs APLM |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$23.00
High
N/A
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-122.00 | $-122.00 | $-122.00 | 1 |
| FY 2027 | $-138.00 | $-138.00 | $-138.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $13.26M | $13.26M | $13.26M | 1 |
| FY 2027 | $20.69M | $20.69M | $20.69M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
